Janus Kinase İnhibitörünün Stabilitesini Değerlendirmeye Yönelik RPLC Metodu Kullanılarak Yapılan Zorunlu Bozunma Çalışmaları
Optimizasyon çalışmalarında, iyonlaşabilen bir fonksiyonel grup içeren bileşiklerin belli kromatografik koşullar altında alıkonma davranışlarını incelemek önemlidir. Bu çalışma da, janus kinaz (JAK) inhibitörü olan tofasitinibin (TOF) kromatografik davranışlarında mobil faz asetonitril (ACN) bileşiminin ve pH’ın etkisi kapsamlıca araştırılmıştır. Öncelikle, pKa ve alıkonma faktörü değerleri kullanılarak kromatografik şartlar optimize edilmiştir. Ardından, geliştirilen metot çeşitli stres testleri altında stabilite çalışmaları ve tabletteki tofasitinibin konsantrasyon belirlenmesinde kullanılmıştır. Son olarak, metot Uluslararası Uyumlaştırma Konferansı (Q2) kılavuzuna göre valide edilmiş ve tofasitinibin bozunma ürünlerinin ayrılmasında başarılı olarak kullanılmıştır. Lineer aralık, tespit ve tayin limitleri sırasıyla 2.0-12.0, 0.416, and 1.260 μg/mL, olarak elde edilmiştir. Gün içi, günler arası doğruluk (RSD%), 4 μg/mL için sırasıyla 0.290 ve0.462 μg/mL bulunmuştur. Bu sonuçlara göre, geliştirilen metot bozunma ürünlerinden ana ilacı ayırmak için oldukça etkilidir.
Forced Degradation Studies to Assess the Stability of a Janus Kinase Inhibitor Using RPLC Method
In optimization studies, it is important to study the retention behavior of the compounds containing the ionizable functional groups under the intended chromatographic conditions. In this study, the influence of pH and acetonitrile (ACN) composition in the mobile phase on chromatographic behavior of tofacitinib (TOF), a Janus kinase (JAK) inhibitor, was thoroughly investigated. First, the chromatographic conditions were optimized using retention factors and pKa values. Then, the developed method was used for the stability studies under various stress conditions, and for the estimation of TOF concentration in tablets. Finally, the method was verified using the International Conference on Harmonization procedure (ICH-Q2) and was successfully used to separate the TOF degradation products. A linearity range, the limits of detection and quantification were confirmed as 2.0-12.0, 0.416, and 1.260 μg/mL, respectively. Between-day and within-day accuracy (RSD%) were found to be as 0.290 and 0.462 for 4 μg/mL, respectively. The result indicates that the developed method is rather effective to isolate the parent drug from the degradation elements.
___
- [1] Ghoreschi, K., Laurence, A., O’shea, J. J. 2009.
Janus kinases in immune cell signaling.
Immunological Reviews, 228, 273-287.
- [2] Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Su
C, Rousell, S., Niezychowski W. 2012. Tofacitinib,
an oral Janus kinase inhibitor, in active
ulcerative colitis. New England Journal of
Medicine, 367, 616-624.
- [3] Papp, K. A., Menter, A., Strober, B., Langley, R. G.,
Buonanno, M., Wolk, R., Gupta, P., Krishnaswami,
S., Tan, H., Harness, J. A. 2012. Efficacy and safety
of tofacitinib, an oral Janus kinase inhibitor, in
the treatment of psoriasis: a Phase 2b
randomized placebo-controlled dose-ranging
study. British Journal of Dermatology, 67, 668-
677.
- [4] Craiglow, B. G., King, B. A. 2014. Killing two birds
with one stone: oral tofacitinib reverses alopecia
universalis in a patient with plaque psoriasis.
Journal of Investigative Dermatology. 134, 2988-
2990.
- [5] Hodge, J. A., Kawabata, T. T., Krishnaswami, S.,
Clark, J. D., Telliez, J. B., Dowty, M. E., Menon, S.,
Lamba, M., Zwillich, S. 2016. The mechanism of
action of tofacitinib-an oral Janus kinase
inhibitor for the treatment of rheumatoid
arthritis. Clinical and Experimental
Rheumatology. 34, 318-328.
- [6] Lloyd, R., Snyder, J., Kirkland, J., Joseph, L. G.,
2002. Practical HPLC method development.
Pinehurst, North Carolina, USA.
- [7] Demiralay, E. C, Alsancak, G., Ozkan, S.A. 2009.
Determination of pKa values of nonsteroidal
antiinflammatory drug-oxicams by RP–HPLC
and their analysis in pharmaceutical dosage
forms. Journal of Separation Science. 32, 2928-
2936.
- [8] Canbay, H. S., Demiralay, E. C., Alsancak, G.,
Ozkan, S. A. 2012. The combined effect of the
organic modifier content and pH of the mobile
phase on the chromatographic behavior of some
arylpropionic and arylacetic acids to optimize
their liquid chromatographic determinations.
Chromatographia, 75, 711-720.
- [9] García-Álvarez-Coque, M. C., Torres-Lapasió, J.
R., Baeza-Baeza, J. J. 2006. Models and objective
functions for the optimization of selectivity in
reversed-phase liquid chromatography.
Analytica Chimica Acta, 579, 125-145.
- [10] Snyder, L. R., Kirkland, J. J., Dolan, J. W. 2010.
Introduction to modern liquid chromatography.
Third edition, A John Wiley&Sons.
- [11] Ortak, H. Y. Demiralay, E. C. 2019. Effect of
temperature on the retention of Janus Kinase 3
inhibitor in different mobile phase compositions
using reversed-phase liquid chromatography.
Journal of Pharmaceutical and Biomedical
Analysis 5, 706-712.
- [12] Sankar, A. S. K., Datchayani, B., Balakumaran, N.,
Mohammed, R., Subaranjani, R. 2017.
Development of a validated reverse phase liquid
chromatographic assay-method for
determination of tofacitinib in pure form and in
physical admixtures. Research Journal of
Pharmacy and Technology, 10, 223-226.
- [13] Prathyusha Naik C. N. Chandra Sekhar K. B.
2018. Novel stability indicating
chromatographic method development and
validation for the quantification of tofacitinib in
pure and its dosage form. IOSR Journal of
Applied Chemistry, 11, 33-37.
- [14] Kiran, B. S. S., Raja, S. 2018. RP-HPLC method
development and validation for the
quantification of tofacitinib. Research Journal of
Life Sciences, Bioinformatics, Pharmaceutical
and Chemical Sciences. 4, 646-653.
- [15] Dowty, M. E., Lin, J., Ryder, T. F., Wang, W.,
Walker, G. S., Vaz, A., Chan, G. L., Krishnaswami,
S., Prakash, C. 2014. The Pharmacokinetics,
Metabolism, and Clearance Mechanisms of
Tofacitinib, a Janus Kinase Inhibitor, in Humans.
Journal of Pharmacology and Experimental
Therapeutics, 348, 165-173.
- [16] Kumar, V., Dhiman, V., Kumar, K., Sharma, G.K.,
Zainuddin, M., Mullangi, R. 2015. Development
and validation of a RP‐HPLC method for the
quantitation of tofacitinib in rat plasma and its
application to a pharmacokinetic study.
Biomedical Chromatography, 29, 1325-1329.
- [17] Sharma, K., Giri, K., Dhiman, V., Dixit, A.,
Zainuddin, M., Mullangi, R. 2015. A validated LC‐
MS/MS assay for simultaneous quantification of
methotrexate and tofacitinib in rat plasma:
application to a pharmacokinetic study.
Biomedical Chromatography, 29, 722-732.
- [18] Kadi, A. A., Abdelhameed, A. S., Darwish, H. W.,
Attwa, M. W. Bakheit, A. H. 2016. Liquid
chromatographic-tandem mass spectrometric
assay for simultaneous quantitation of
tofacitinib, cabozantinib and afatinib in human
plasma and urine. Tropical Journal of
Pharmaceutical Research, 15, 2683-2692.
- [19] Wu, X., Zeng, X., Wang, L., Hang, T. and Song, M.,
2017. Identification of related substances in
tofacitinib citrate by LC-MS techniques for
synthetic process optimization. Journal of
Pharmaceutical and Biomedical Analysis, 143,
17-25.
- [20] Barbosa, J. Sanz-Nebot, V. 1992. pH
measurements in acetonitrile-water mixtures by
use of a glass electrode. Journal of Pharmaceutical and Biomedical Analysis, 10,
1047-1051.
- [21] Rondinini, S., Mussini, P. R., Mussini T. 1987.
Reference value standards and primary
standards for pH measurements in Organic
Solvents and Water + Organic Solvent Mixtures
of Moderate to High Permittivity’s.
Pure and Applied Chemistry, 59(11), 1549-1560.
- [22] Yilmaz H., Demiralay, E. Ç. 2015. Investigation of
chromatographic behavior of leflunomide and
its identification in pharmaceutical dosage form
by reversed phase liquid chromatography.
Journal of Liquid Chromatography & Related
Technologies, 38, 1.
- [23] Stout, R. W., De Stefano, J. J., Snyder, L. R. 1983.
High-performance liquid chromatographic
column efficiency as a function of particle
composition and geometry and capacity factor.
Journal of Chromatography A, 282, 263-286.
- [24] International Conference on Harmonisation,
2003. International conference on
harmonization of technical requirements for
registration of pharmaceuticals for human use,
topic Q1A (R2): stability testing of new drug
substances and products.
- [25] Dogan Daldal, Y., Çakır, C., Yılmaz, H., Cubuk
Demiralay, E., A Ozkan, S., Alsancak, G., 2014.
Liquid Chromatographic, Spectrophotometric
and Potentiometric pKa Determination of
Ranitidine and Famotidine. Current Drug
Therapy, 9(4), 277-284.
- [26] Yilmaz, H., Cobandede, Z., Yilmaz, D., Cinkilic, A.,
Culha, M., Demiralay, E. C. 2020. Monitoring
forced degradation of drugs using silica coated
AgNPs with surface-enhanced Raman scattering.
Talanta, 214(1), 120828.